<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04827368</url>
  </required_header>
  <id_info>
    <org_study_id>20-1149</org_study_id>
    <secondary_id>B19-566</secondary_id>
    <nct_id>NCT04827368</nct_id>
  </id_info>
  <brief_title>Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease</brief_title>
  <acronym>VOC</acronym>
  <official_title>Non-invasive Disease Activity Monitoring in Patients With Inflammatory Bowel Disease (IBD) Using Volatile Organic Compounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory Bowel Disease (IBD) are chronic diseases of the gut comprising Crohn's Disease&#xD;
      (CD) and Ulcerative Colitis (UC). The symptoms of IBD consist of diarrhea, abdominal&#xD;
      discomfort, weight loss, fatigue and rectal bleeding. However, symptoms and treatment vary&#xD;
      between patients. Early management of IBD can lead to better response rates and decrease the&#xD;
      risk of irreversible bowel damage and future disease complications such as surgeries. Current&#xD;
      clinical tools for diagnosis and or assessing progression of IBD are either invasive&#xD;
      (colonoscopy), have low patient acceptance (fecal calprotectin) or low accuracy (C-reactive&#xD;
      protein). The purpose of this study is to collect clinical data and samples (including blood,&#xD;
      breath and stool) donated by patients with IBD and patients with no IBD (controls) to&#xD;
      facilitate research that may result in the development of new non-invasive methods of&#xD;
      diagnosing IBD and understand the progression of the disease over time in order to better&#xD;
      manage IBD patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Breath volatile organic compounds (VOC)s and objective markers of Inflammatory Bowel Disease (IBD) Activity</measure>
    <time_frame>1 year</time_frame>
    <description>Correlation of breath VOCs with changes in Fecal Calprotectin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breath volatile organic compounds (VOC)s and objective markers of Inflammatory Bowel Disease (IBD) Activity</measure>
    <time_frame>1 year</time_frame>
    <description>Correlation of breath VOCs with changes in C-reactive protein (CRP) and clinical disease activity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Breath volatile organic compounds (VOC)s and objective markers of Inflammatory Bowel Disease (IBD) Activity</measure>
    <time_frame>1 year</time_frame>
    <description>Correlation of breath VOCs with endoscopic disease activity</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>IBD</condition>
  <condition>Crohn Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Crohns Disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulcerative Colitis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-IBD</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Breath Test</intervention_name>
    <description>Research Breath Test</description>
    <arm_group_label>Crohns Disease</arm_group_label>
    <arm_group_label>Non-IBD</arm_group_label>
    <arm_group_label>Ulcerative Colitis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from the Inflammatory Bowel Disease Center with scheduled colonoscopies for&#xD;
        standard of care visits.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed as having Crohn's Disease or Ulcerative Colitis&#xD;
&#xD;
          -  Aged 18-70 years.&#xD;
&#xD;
          -  Understands the language and signs an informed consent form.&#xD;
&#xD;
          -  Any disease location, except isolated upper GI Crohn's disease only&#xD;
&#xD;
          -  Any CD or UC disease activity.&#xD;
&#xD;
          -  Outpatients and inpatients&#xD;
&#xD;
          -  Patients will be recruited, and samples obtained at least one day, and no more than&#xD;
             one week, prior to out/inpatient colonoscopy preparation to allow objective assessment&#xD;
             of disease activity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Status post colectomy&#xD;
&#xD;
          -  Status post diverting loop ileostomy or end ileostomy or colostomy&#xD;
&#xD;
          -  On antibiotics in the past 3 months or currently&#xD;
&#xD;
          -  Women (pregnant or breast feeding)&#xD;
&#xD;
          -  Subjects with concurrent chronic liver, renal, lung or metabolic disorders&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Bowel preparation at day of sample procurement&#xD;
&#xD;
          -  Isolated upper GI Crohn's disease only&#xD;
&#xD;
          -  Active disease on colonoscopy, but normal fecal calprotectin at inclusion&#xD;
&#xD;
          -  C diff. positive at time of inclusion (test to be obtained in routine clinical care).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Rieder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nita Hoxha</last_name>
    <phone>216-445-5297</phone>
    <email>hoxhan2@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NITA HOXHA, MBA</last_name>
      <phone>216-445-5297</phone>
      <email>HOXHAN2@CCF.ORG</email>
    </contact>
    <investigator>
      <last_name>Florian Rieder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Taha Qazi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Florian Rieder</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>IBD, VOC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

